Enzyme

Yeast Market, Size, Global Forecast 2024-2030: Nutrition Demands Fuels Expansion into Diverse Sectors, Including Biofuels and Pharmaceuticals - ResearchAndMarkets.com

Retrieved on: 
torsdag, maj 9, 2024
Food, Beverage, Retail, Snack, Enzyme, Food quality, Wine, Beer, Respiration, Plasma protein binding, Vitamin, Transport, Vaccine, Biofuel, Automation, Food industry, Incidence, Biotechnology, Bread

Global demand for yeast is surging, driven by the need for fresh bread, pastries, and baked items in bakeries and houses internationally.

Key Points: 
  • Global demand for yeast is surging, driven by the need for fresh bread, pastries, and baked items in bakeries and houses internationally.
  • The comfort trend boosts the popularity of ready-to-bake products with yeast, providing an easy way to experience freshly baked items.
  • Yeast, identified for its dietary richness in vitamin B, protein, and fiber, finds utility in diverse sectors.
  • The country's affinity for diverse cuisines, from traditional bread to modern fermented products, amplifies yeast utilization.

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

Retrieved on: 
måndag, maj 6, 2024
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Other Technology, Software, Artificial Intelligence, Clinical Trials, Enzyme, Cancer, Prostate, IP, D.C, PDI, Proteinopathy, PMID, Drug resistance, Machine learning, The Journal of Pathology, Breast, MD, Cell, Artificial intelligence, Leukemia, ISSN, Cancer Medicine, Molecular biology, CNS, Giaquinto, Algorithm, Patient, Neoplasm, Lung, Death, Head, Biomarker, Drug development, Therapy, Clinician, Journal, Ovarian cancer, Brain, Oncology Reports, Pharmaceutical industry

(NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI) (1) inhibitor drug candidate XCE853 in novel and targeted cancer indications.

Key Points: 
  • (NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI) (1) inhibitor drug candidate XCE853 in novel and targeted cancer indications.
  • Oregon Therapeutics is developing XCE853 in various cancer indications, including drug-resistant ovarian and pancreatic cancer, certain hematological cancers and several pediatric cancers including CNS cancers.
  • Oregon Therapeutic’s lead drug-candidate XCE853 is known to target PDIs of specific interest for cancer.
  • Oregon Therapeutics is entitled to financial benefits resulting from the out licensing of the background IP to Lantern Pharma.

Upkara seeks partnerships for breakthrough biomolecule stabilization technology under leadership of new CEO

Retrieved on: 
onsdag, maj 8, 2024
ANN, CMV, Freezing, Enzyme, Antibody, Dicarboxylic acid, Water, Fine chemical

The novel stabilization technology , called capillary-mediated vitrification (CMV), quickly evaporates water from samples without the freezing step that makes lyophilization expensive, time consuming, and results in reduced product yields.

Key Points: 
  • The novel stabilization technology , called capillary-mediated vitrification (CMV), quickly evaporates water from samples without the freezing step that makes lyophilization expensive, time consuming, and results in reduced product yields.
  • The technology streamlines product development and manufacturing, reduces supply chain risks, curtails expenses, expands market access, and improves sustainability.
  • Upkara offers licensing of their stabilization technology to commercial reagent and kit manufacturers for integration onto manufacturing lines, or customers can contract Upkara to provide stabilization services.
  • "I'm tremendously excited to engage with partners across the biotechnology industry to demonstrate the transformative potential of our stabilization technology on manufacturing lines," says new CEO, Rich Troyer.

Molecular Assemblies Launches Partner Program for Onsite Synthesis of Long, Pure, Accurate DNA

Retrieved on: 
tisdag, maj 7, 2024
Doctor of Philosophy, Enzyme, Gene editing, Partnership, Research, MAI, UC, NGS, Protein engineering, Oligonucleotide, DNA, Therapy, Booth, Synthetic biology, University of California, Berkeley, Biotechnology, SAN, Fine chemical

SAN DIEGO, May 7, 2024 /PRNewswire/ -- Molecular Assemblies, Inc., ("MAI" or the "Company") a pioneer and leader in the field of enzymatic DNA synthesis, today announced the launch of its Partnering Program to license Molecular Assemblies' Fully Enzymatic SynthesisTM (FESTM) technology for onsite synthesis. FES technology accelerates the production of long, pure, and accurate DNA to power a new rapidly emerging generation of therapeutics and diagnostics.

Key Points: 
  • SAN DIEGO, May 7, 2024 /PRNewswire/ -- Molecular Assemblies, Inc. , ("MAI" or the "Company") a pioneer and leader in the field of enzymatic DNA synthesis, today announced the launch of its Partnering Program to license Molecular Assemblies' Fully Enzymatic SynthesisTM (FESTM) technology for onsite synthesis.
  • FES technology accelerates the production of long, pure, and accurate DNA to power a new rapidly emerging generation of therapeutics and diagnostics.
  • Molecular Assemblies also announced today that the company has opened early access to order oligonucleotides up to 400mer in length, limited to the first 20 customers.
  • Molecular Assemblies' Fully Enzymatic SynthesisTM (FESTM) is the foundation of their approach to create long, high quality, sequence specific DNA composed of more than 300 base pairs.

GreenLab Partners with Ginkgo Bioworks to Scale Up Production of Brazzein, a Novel Sweetener

Retrieved on: 
tisdag, maj 7, 2024
Deployment, Enzyme, PFAS, Sucrose, Risk, Business development, Partnership, Ginkgo, Plant, Obesity, Ginkgo Bioworks, DNA, Food, Laccase, Fruit, Brazzein, Biotechnology, Fine chemical

JONESBORO, Ark. and BOSTON, May 7, 2024 /PRNewswire/ -- GreenLab, an emerging next generation plant-biotechnology company producing complex proteins in corn, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Together, GreenLab and Ginkgo aim to enable production of brazzein, a sweet-tasting protein found in the fruit of the native West African Oubli plant, at commercial scale. The two companies have previously partnered on a project to develop an enzyme for GreenLab's PFAS degradation application.

Key Points: 
  • Together, GreenLab and Ginkgo aim to enable production of brazzein, a sweet-tasting protein found in the fruit of the native West African Oubli plant, at commercial scale.
  • The two companies have previously partnered on a project to develop an enzyme for GreenLab's PFAS degradation application.
  • By producing proteins in a cultivated crop, GreenLab can readily scale production across acres of cornfields, with little additional up-front capital and infrastructure.
  • Karen Wilson, CEO of GreenLab: "GreenLab is eager to work with Ginkgo on this novel go-to-market strategy.

Green Plains Reports First Quarter 2024 Financial Results

Retrieved on: 
fredag, maj 3, 2024
Alternative Energy, Energy, Agriculture, Natural Resources, Sequence, Glucose, Negotiation, Gasoline, Yeast, Aviation biofuel, Food safety, Enzyme, Mergers and acquisitions, Partner, Policy, Natural gas, Depreciation, Partnership, Biopolymer, Transport, Carbon, Ethanol, Plant, Obion, Tennessee, JV, Eye, Corn oil, Acquisition, Food, Marketing, Becker

Green Plains Inc. (NASDAQ:GPRE) (“Green Plains” or the “company”) today announced financial results for the first quarter of 2024.

Key Points: 
  • Green Plains Inc. (NASDAQ:GPRE) (“Green Plains” or the “company”) today announced financial results for the first quarter of 2024.
  • Revenues were $597.2 million for the first quarter of 2024 compared with $832.9 million for the same period last year.
  • The consolidated ethanol crush margin was ($9.3) million for the first quarter of 2024, compared with ($12.5) million for the same period in 2023.
  • Intersegment activities between the partnership and Green Plains Trade associated with terminal services transacted with the agribusiness and energy services segment will continue to be eliminated on a consolidated level.

Small Molecule Shows Early-Stage Promise for Repairing Myelin Sheath Damage

Retrieved on: 
torsdag, maj 2, 2024
Nerve, Brain, Enzyme, University, Cell nucleus, Mouse, Tissue, H3K9me3, Organoid, Thought, H3K27ac, Doctor of Philosophy, Axon, Research, Remyelination, Disease, OLS, Cholesterol, Movement, Gene expression, Multiple sclerosis, Regeneration, Ageing, H3K27me3, Tetraplegia, Pharmaceutical industry

CINCINNATI, May 2, 2024 /PRNewswire/ -- When treated with a novel protein function inhibitor called ESI1, mice that mimic the symptoms of multiple sclerosis (MS) and lab-prepared human brain cells both demonstrated the ability to regenerate vital myelin coatings that protect healthy axon function.

Key Points: 
  • When the protective myelin gets damaged, be it by disease or the wear and tear of age, nerve signaling gets disrupted.
  • Pinning down the genetic changes and signals involved in the repair silencing process and finding a small molecule compound that can reverse the silencing was a complex undertaking.
  • In both aging mice and mice mimicking MS, the ESI1 treatment prompted myelin sheath production and improved lost neurological function.
  • When the organoids were exposed to ESI1, the treatment extended the myelin sheath of myelinating cells, the study reports.

Shineco Develops Revolutionary New Product with Varied Applications to Positively Impact the Health Care Industry

Retrieved on: 
onsdag, maj 1, 2024
Conditional sentence, Brain, Drug, Enzyme, Patient, Bone marrow, Acetone, Organelle, Soybean, Inflammation, Methane, Protein, Cell, Laboratory, Mineral, Pregnancy, Blood, Yolk, Health, Apoptosis, Human body, Death, Research, Vitamin, Water, Carbon, Functional food, Phospholipid, Kaifeng, Dietary fiber, Disease, Convalescence, Agonal respiration, Human, Mitochondrion, SISI, Food, Medicine, PC, Golgi, Carbohydrate, Nutrient, Beauty, Signal transduction, Temperature, Ageing, Microsome, Lipid, Cell damage, Malabsorption, Growth, Fats, Phosphorus

Cells are the basic units of life, and the health and vitality of cells directly affect the health of the entire body.

Key Points: 
  • Cells are the basic units of life, and the health and vitality of cells directly affect the health of the entire body.
  • Cells need to continuously obtain nutrients from the external environment to support their normal growth, division and metabolic activities.
  • When cells receive sufficient and balanced nutrients, they can maintain optimal conditions, perform various life activities, and maintain cell health.
  • The layout of the three major fields will create natural active water phospholipids into a super new category in the health industry.

EQS-News: BRAIN Biotech AG takes next step to optimize group structure

Retrieved on: 
fredag, maj 3, 2024
CFO, Social group, BRAIN, BioScience, Supervisory board, Enzyme

BRAIN Biotech Group will merge AnalytiCon Discovery GmbH into BRAIN Biotech AG in order to further optimize and simplify the Group structure.

Key Points: 
  • BRAIN Biotech Group will merge AnalytiCon Discovery GmbH into BRAIN Biotech AG in order to further optimize and simplify the Group structure.
  • Zwingenberg, Germany, 16 April 2024 – The Management Board of BRAIN Biotech AG, with the approval of the Supervisory Board, has resolved to merge AnalytiCon Discovery GmbH with BRAIN Biotech AG.
  • AnalytiCon Discovery GmbH, based in Potsdam, Germany, is already a fully owned subsidiary of the BRAIN Biotech Group.
  • This legal reorganization will further optimize and simplify the structure of the BRAIN Biotech Group.

Bestqool proves the effectiveness and safety of its red light therapy device with a professional third-party Report

Retrieved on: 
onsdag, april 17, 2024
Physical, Enzyme, Cell, RLT, Safety, Skin, Tissue, Bacteria, NASA, Weight loss, System, Carbon, Plant, Mitochondrion, Oxygen, Phagocytosis, Vasodilation, Medicine, Virus, Nutrient, Regeneration, Food preservation

Bestqool , a leading manufacturer in the industry of red light therapy, offers lifestyle game-changing devices that prioritize safety, efficacy, and user comfort.

Key Points: 
  • Bestqool , a leading manufacturer in the industry of red light therapy, offers lifestyle game-changing devices that prioritize safety, efficacy, and user comfort.
  • The utilization of red light therapy in well-being has its roots dating back to ancient Greek times.
  • Unlike ultraviolet light, red light is harmless to the skin and does not tan or cause dark spots to the skin.
  • One of the crucial factors that the reader needs to pay attention to when buying red light therapy is RLT device irradiance.